Plain-English translation of NCT05920798 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
The FRAPPE trial is testing a new combination treatment for ovarian cancer that has returned after prior therapy. The treatment combines a personalized vaccine called MC220601 (made from your own immune cells) with , an immunotherapy medication that helps your body's immune system fight cancer. Researchers want to see if this combination is safe and effective at controlling recurrent ovarian cancer.
Ovarian cancer that comes back after initial treatment is difficult to manage, and many patients need better treatment options. This medication and vaccine combination is designed to train your immune system to specifically recognize and attack ovarian cancer cells, offering a new way to fight the disease.
You likely qualify if…
You likely don't qualify if…
First, you'll have a procedure called apheresis where blood is drawn from your arm, special immune cells are collected, and the blood is returned to your body — this vaccine is then made from your own cells. Over the next several months, you'll receive the vaccine and infusions on a set schedule (every 3 weeks for the first 8 cycles, then every 6 weeks after that), with regular CT or MRI scans, blood tests, and possibly a biopsy to monitor how well the treatment is working. You'll need to be willing to travel to Mayo Clinic for these visits and provide blood samples throughout the trial.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States